Patents by Inventor Blain Mamiya

Blain Mamiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for modulation and inhibition of telomerase
    Patent number: 6593306
    Abstract: It was found that normal human stem cells produce a regulated non-processive telomerase activity, while cancer cells produce a processive telomerase activity. Nucleotide analogs, such as 7-deaza-2′-deoxyquanosine-5′-triphosphate (7-deaza-dGTP) were found to be substrates for processive telomerase and incorporated into telomeric sequence. The incorporation of this nucleotide subsequently affected the processivity of telomerase, converting processive telomerase to non-processive telomerase. The incorporation of this nucleotide analogs was also found to inhibit formation of G-quartets by telomeric sequence. Other methods for converting cancer processive telomerase to the more benign non-processive telomerase include partially cleaving the telomerase RNA.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: July 15, 2003
    Assignees: Board of Regents, The University of Texas Systems, CTRC Research Foundation
    Inventors: Shih-Fong Chen, Ira Maine, Sean M. Kerwin, Terace M. Fletcher, Miquel Salazar, Blain Mamiya, Makoto Wajima, Bradford E. Windle
  • Methods and compositions for modulation and inhibition of telomerase in vitro
    Patent number: 6054442
    Abstract: It was found that normal human stem cells produce a regulated non-processive telomerase activity, while cancer cells produce a processive telomerase activity. Nucleotide analogs, such as 7-deaza-2'-deoxyquanosine-5'-triphosphate (7-deaza-dGTP) were found to be substrates for processive telomerase and incorporated into telomeric sequence. The incorporation of this nucleotide subsequently affected the processivity of telomerase, converting processive telomerase to non-processive telomerase. The incorporation of this nucleotide analogs was also found to inhibit formation of G-quartets by telomeric sequence. Other methods for converting cancer processive telomerase to the more benign non-processive telomerase include partially cleaving the telomerase RNA.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: April 25, 2000
    Assignees: Board of Regents, University of Texas System, CTRC Research Foundation
    Inventors: Shih-Fong Chen, Ira Maine, Sean M. Kerwin, Terace M. Fletcher, Miguel Salazar, Blain Mamiya, Bradford E. Windle, Makoto Wajima
  • Methods for modulation and inhibition of telomerase
    Patent number: 6004939
    Abstract: It was found that normal human stem cells produce a regulated non-processive telomerase activity, while cancer cells produce a processive telomerase activity. Nucleotide analogs, such as 7-deaza-2'-deoxyquanosine-5'-triphosphate (7-deaza-dGTP) were found to be substrates for processive telomerase and incorporated into telomeric sequence. The incorporation of this nucleotide subsequently affected the processivity of telomerase, converting processive telomerase to non-processive telomerase. The incorporation of this nucleotide analogs was also found to inhibit formation of G-quartets by telomeric sequence. Other methods for converting cancer processive telomerase to the more benign non-processive telomerase include partially cleaving the telomerase RNA.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: December 21, 1999
    Assignees: CTRC Research Foundation Board of Regents, The University of Texas System
    Inventors: Shih-Fong Chen, Ira Maine, Sean M. Kerwin, Terace M. Fletcher, Miquel Salazar, Blain Mamiya, Makoto Wajima, Bradford E. Windle